In order to ensure that you continue to receive information that is of interest from PharmaVentures help us by subscribing. Thank you for your co-operation. PharmaVentures Intelligence Report - A Guide to Royalty Rates in Pharmaceutical Licensing Deals This indispensable report is a must read for anyone involved in deal making. It sheds light on the complex area of Royalty Rates using real life examples and case studies. Read more... More information on this or any of our other reports Market News and Trends August was a relatively quiet time for the announcement of drug delivery deals. Nevertheless, a significant deal was announced relating to Nektar Therapeutics' acquisition of Aerogen, Inc. Aerogen's technology, an electronic micropump allowing the inhalation of liquids, will complement Nektar's powder technology and so enhance the capabilities of its acute care treatments, notably its inhaled insulin product for diabetes. Read more... Featured Article SonoPrep® Ultrasonic Skin Permeation Science and Drug Delivery Applications Transdermal drug delivery is affected by various factors that influence the transfer of the drug into and through skin layers and uptake by capillaries for system drug delivery applications. Ultrasonic skin permeation has the potential to change the paradigms of transdermal drug delivery that limit applications to small molecules, chronic applications and potent drugs. Thomas Davison, Sontra Medical, discusses the use of ultrasonic skin permeation. Read more... Company Profiles 3M, BASF, Eurand, Fertin Drug Delivery Opportunities View all our Drug Delivery Opportunities or alternatively request a password to submit your opportunity online. Featured Opportunity Inhaled Fentanyl for Cancer Breakthrough Pain Administrative route - Inhalation Indication - Cancer breakthrough pain Licence code LO-0805-01 Ensure you receive your copy of the Drug Delivery Companies Report Autumn/Winter 2005 For deal makers actively assessing drug delivery technology receiving your complimentary copy is a must. The DDR blends high-quality articles covering the latest drug delivery developments in conjunction with concise profiles of companies active in specific technology areas. Please submit your details by 30th September to ensure you are added to the controlled circulation list. Find out more about promoting your company.
Drug Delivery E-News is produced by PharmaVentures Intelligence, part of PharmaVentures - a leading results driven organisation assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence, we work with clients to drive greater value from their deals. If you do not wish to receive DDR E-News in future, please e-mail ddcr@pharmamail.biz with the words UNSUBSCRIBE as the subject. If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddcr@pharmamail.biz with REMOVE as the subject. For more details contact Paul Sanders, Product Manager, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail enquiries@ddcr.com www.ddcr.com